Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
Latest Information Update: 26 Sep 2022
At a glance
- Drugs Sargramostim (Primary)
- Indications Pulmonary alveolar proteinosis
- Focus Adverse reactions
- Acronyms PharmPAP
- 02 Aug 2021 Status changed from recruiting to completed.
- 26 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 26 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.